Previously, in similar studies we have shown that as early as at 6 hours of signaling inhibition, the irreversible EGFR inhibitor, CL-387,785 could induce a significant change of transcription in a small and representative group of key downstream effectors of oncogenic EGFR signaling, including important pathway components such as Cyclin D1, DUSPs etc in EGFR mutant lung cancers [1], [26], [27]. This evidence concerns the gene EGFR and lung carcinoma.